RGLS
Regulus Therapeutics Inc. [RGLS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RGLS Stock Summary
Top 10 Correlated Stocks
RGLS
In the News
RGLS Financial details
Company Rating
-
Market Cap
183.3M
Income
-29.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.87
Forward P/E
-
PEG
0.6
P/S
-
P/B
0.89
P/C
-
P/FCF
-0.94
Quick Ratio
3.73
Current Ratio
4.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-15.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.88%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
100%
SMA50
100%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-76%
ROE
-94%
ROC
-1.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.08-3.79
52W High
-40.7%
52W Low
+77.9%
RSI
69
Rel Volume
0.75
Avg Volume
3.14M
Volume
2.36M
Perf Week
36.85%
Perf Month
40.08%
Perf Quarter
20.2%
Perf Half Y
10.5%
-
-
-
-
Beta
1.549
-
-
Volatility
0.17%, 0.16%
Prev Close
1.66%
Price
1.779
Change
2.83%
Company Profile
- Volume Average 3.14M
- Market Capitalization 183.3M
- Employee 30
- CEO Mr. Joseph P. Hagan M.B.A.
- Headquarters San Diego,CA,US
- IPO Date 2012-10-09
-
Website
https://www.regulusrx.com 
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
